Clinical Trials on Malignant Carcinoid Syndrome

Total 59896 results

H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Neuroendocrine Carcinoma

United States
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Carcinoid Syndrome

United States
Lexicon Pharmaceuticals

Completed

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Carcinoid Syndrome

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Canada, Israel
Boston Medical Center
Amgen

Withdrawn

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Carcinoid Syndrome

United States
Ipsen

Completed

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome (ELECT)

Carcinoid Syndrome

United States, Turkey, Brazil, India, Ukraine, South Africa, Czechia, Latvia, Poland, Russian Federation, Serbia
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms (TELEPATH)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate for Carcinoid Syndrome Therapy (TELECAST)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Spain, Sweden, United Kingdom, Netherlands
Endo Pharmaceuticals

Terminated

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

Carcinoid Syndrome

United States
Ipsen

Terminated

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome (CAMPANULA)

Carcinoid Syndrome

Spain, Belgium, Ireland, Czechia, Israel, France, United Kingdom, Latvia, Germany, Russian Federation, Slovakia, Italy, Netherlands, Finland, Austria, Poland, Sweden, Ukraine
Ipsen

Terminated

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Malignant Carcinoid Syndrome

United States
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Carcinoid Syndrome

Germany, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield

Completed

Effects of Serotonin Excess on Bone in Carcinoid Syndrome

Carcinoid Syndrome

United Kingdom
Ipsen

Completed

Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain (RECOSY)

Neuroendocrine Tumors

Spain
Chandrikha Chandrasekhara
TerSera Therapeutics LLC

Withdrawn

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NET-PACS)

Diarrhea | Neuroendocrine Tumors | Carcinoid Syndrome

United States
Cliniques universitaires Saint-Luc- Université...

Terminated

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation (SCIROCCO)

Neuroendocrine Tumors | Carcinoid Syndrome
M.D. Anderson Cancer Center

Withdrawn

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

Carcinoid Syndrome | Advanced Neuroendocrine Neoplasm
Ipsen

Completed

A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea (SYMNET)

Neuroendocrine Tumors | Carcinoid Syndrome

France, Italy, United Kingdom, Poland, Spain, Hungary, Czechia, Israel
TerSera Therapeutics LLC

Completed

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO (RELAX)

Carcinoid Syndrome

United States
Novartis Pharmaceuticals

Completed

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (RADIANT-2)

Carcinoid Tumor | Malignant Carcinoid Syndrome

France, Spain, Netherlands, United States, Canada, Sweden, Italy, Australia, Germany, Greece, Belgium, Czech Republic, Slovakia, Finland, United Kingdom
Lexicon Pharmaceuticals

Completed

An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males (LX1606-104)

Carcinoid Syndrome

United Kingdom
Vanderbilt-Ingram Cancer Center
Entrinsic Bioscience Inc.

Terminated

Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

Neuroendocrine Tumor | Carcinoid Syndrome

United States
King's College Hospital NHS Trust
Advanced Accelerator Applications

Not yet recruiting

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy (CHARRT)

Carcinoid Tumor | Carcinoid Syndrome | Carcinoid Heart Disease
University of Chicago
Stand Up To Cancer

Recruiting

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

Cancer | Malignant Neoplasm | Malignancy

United States
M.D. Anderson Cancer Center

Recruiting

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Carcinoid Tumor | Carcinoid Syndrome | Metastatic Carcinoid Tumor | Digestive System Neuroendocrine Tumor G1

United States
European Organisation for Research and Treatment...
Ipsen

Withdrawn

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome (TELEFIRST)

Small Intestinal NET | Carcinoid Heart Disease
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

Carcinoid Syndrome | Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm

United States
Hospices Civils de Lyon

Not yet recruiting

Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors (CRUSOE-NETs)

Carcinoid Heart Disease

France
Queen Mary University of London
Royal Free Hospital NHS Foundation Trust

Active, not recruiting

Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease (TRICAR)

Carcinoid Syndrome | Carcinoid Heart Disease | Tricuspid Regurgitation | Tricuspid Valve Disease

United Kingdom
Joaquina Baranda

Active, not recruiting

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Cancer | Solid Tumor | Malignant Disease | Relapsed Hematologic Malignancy

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Azilect + Antidepressant Chart Review (STACCATO)

Serotonin Syndrome
Crinetics Pharmaceuticals Inc.

Active, not recruiting

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Carcinoid Tumor | Carcinoid Syndrome | Carcinoid | Carcinoid Tumor of Ileum | Carcinoid Tumor of Cecum | Carcinoid Syndrome Diarrhea | Carcinoid Intestine Tumor | Carcinoid Tumor of Liver | Carcinoid Tumor of Pancreas

United States, Brazil, Argentina, Canada, Mexico, Peru, Poland
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Neuroendocrine Tumor | Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA Syndrome

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA Syndrome

United States
Lowell Anthony, MD
Entrinsic Bioscience Inc.

Completed

Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs

Diarrhea | Neuroendocrine Tumors | Carcinoid Syndrome | Carcinoid Tumor of GI System

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Metastatic Skin Squamous Cell Carcinoma | Metastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Refractory Malignant Neoplasm | Appendix Adenocarcinoma | Locally Advanced Malignant Neoplasm | Skin Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma | Metastatic Small... and other conditions

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Pulmonary Carcinoid Tumor

Canada
National Cancer Institute (NCI)

Completed

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Regional Gastrointestinal Carcinoid Tumor

United States
Royal Marsden NHS Foundation Trust
University College London Hospitals; University of Southampton; St George's University... and other collaborators

Completed

Information Needs Around Parenteral nUTrition in Cancer (INPUT)

Neoplasms | Cancer | Tumor | Malignant Neoplasm | End Stage Cancer | Malignancy | Terminal Cancer

United Kingdom
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Withdrawn

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Gastrointestinal Carcinoid Tumor | Islet Cell Carcinoma
Mid-Atlantic Oncology Program
Cancer Biotherapy Research Group

Completed

Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors

Lung Cancer | Gastrointestinal Carcinoid Tumor

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Pulmonary Carcinoid Tumor

United States
Molecular Insight Pharmaceuticals, Inc.

Withdrawn

Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors

Malignant Carcinoid Tumor
National Cancer Institute (NCI)

Terminated

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Regional Gastrointestinal Carcinoid Tumor | Pulmonary Carcinoid Tumor

United States
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Neoplasms | Malignant Carcinoma

United States, France
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome

United States
Federation Francophone de Cancerologie Digestive

Completed

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome
Immunovia, Inc.

Completed

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

Pancreatic Ductal Adenocarcinoma | Familial Pancreatic Cancer | FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome

United States, Sweden, Canada, Spain, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast Carcinoma

United States
University of Edinburgh

Recruiting

Fibrosis in Chronic and Delayed Myocardial Infarction (FCDMI)

Aortic Stenosis | Carcinoid Syndrome | Chemotherapy Induced Systolic Dysfunction

United Kingdom
M.D. Anderson Cancer Center

Active, not recruiting

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Carcinoma in the Liver | Metastatic Carcinoma in the Lung | Metastatic Malignant Neoplasm in the Thoracic Cavity

United States

Clinical Trials on Malignant Carcinoid Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations